Product NDC: | 0615-1338 |
Proprietary Name: | Terazosin Hydrochloride |
Non Proprietary Name: | Terazosin |
Active Ingredient(s): | 2 mg/1 & nbsp; Terazosin |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0615-1338 |
Labeler Name: | NCS HealthCare of KY, Inc dba Vangard Labs |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA074823 |
Marketing Category: | ANDA |
Start Marketing Date: | 19980330 |
Package NDC: | 0615-1338-39 |
Package Description: | 30 CAPSULE in 1 BLISTER PACK (0615-1338-39) |
NDC Code | 0615-1338-39 |
Proprietary Name | Terazosin Hydrochloride |
Package Description | 30 CAPSULE in 1 BLISTER PACK (0615-1338-39) |
Product NDC | 0615-1338 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Terazosin |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 19980330 |
Marketing Category Name | ANDA |
Labeler Name | NCS HealthCare of KY, Inc dba Vangard Labs |
Substance Name | TERAZOSIN HYDROCHLORIDE |
Strength Number | 2 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |